Literature DB >> 26792290

Aminoglycoside use in a pediatric hospital: there is room for improvement-a before/after study.

Mélanie Houot1, Benoit Pilmis2, Valérie Thepot-Seegers3, Clémence Suard1, Cyrielle Potier1, Martine Postaire1, Jean-Ralph Zahar4,5.   

Abstract

UNLABELLED: Aminoglycoside prescriptions were rarely evaluated in children care facilities. Because of risk of toxicity, these narrow spectrum antibiotics are commonly misused. In this study, we evaluate aminoglycoside prescription and assess the impact of an information campaign on modalities of prescription and monitoring practices in a pediatric hospital. This prospective study, before/after diffusion of local recommendations, has been conducted over 6 months. All computerized prescriptions were analyzed. A semi-passive diffusion of local recommendations to prescribers allowed researchers to differentiate between a pre-intervention (P1) and post-intervention period (P2). Endpoints were the improvement of administered doses (mg/kg), modalities of administration, treatment duration, indications, and the presence of pharmacological monitoring. Three hundred and ten prescriptions were analyzed (P1 = 163, P2 = 147). Most common sites of infection treated were as follows: joint-bone (33 %), urinary tract (17 %) and intra-abdominal (15 %). Among all prescriptions, respectively, 12 and 13 % were avoidable. Short-duration treatment and single daily dosing seem to be widely achieved, but despite an improvement between the two periods, 45 % of prescribed doses in P2 were still below our recommendations (77 % in P1).
CONCLUSION: The semi-passive diffusion of recommendations has not improved significantly medical practices. Active diffusion with a regular monitoring could be useful to improve the use of aminoglycosides. WHAT IS KNOWN: • Misuse of aminoglycosides has been frequently described and evaluated in adult hospitals. • This misuse could be explained by their nephrotoxicity and their low therapeutic index. What is New: • Through this study, conducted in a pediatric hospital, we highlighted that practitioners misunderstand the aminoglycoside pharmacokinetic and pharmacodynamic targets and 12.3 % of aminoglycoside prescriptions could be avoided. • Finally, we showed that a semi-passive diffusion of local recommendations is not enough to improve aminoglycoside prescriptions.

Entities:  

Keywords:  Aminoglycosides; Audit; Information campaign; Pediatrics

Mesh:

Substances:

Year:  2016        PMID: 26792290     DOI: 10.1007/s00431-016-2691-0

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  26 in total

Review 1.  Why don't physicians follow clinical practice guidelines? A framework for improvement.

Authors:  M D Cabana; C S Rand; N R Powe; A W Wu; M H Wilson; P A Abboud; H R Rubin
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

Review 2.  Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis.

Authors:  M Paul; I Silbiger; S Grozinsky; K Soares-Weiser; L Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

3.  Changing attitudes to infection management in primary care: a controlled trial of active versus passive guideline implementation strategies.

Authors:  C W Onion; C A Bartzokas
Journal:  Fam Pract       Date:  1998-04       Impact factor: 2.267

4.  Evaluation of a computer-assisted antibiotic-dose monitor.

Authors:  R S Evans; S L Pestotnik; D C Classen; J P Burke
Journal:  Ann Pharmacother       Date:  1999-10       Impact factor: 3.154

5.  An information campaign on aminoglycosides use during septic shock failed to improve the quality of care.

Authors:  M-O Fischer; J-J Parienti; C Daurel; D Debruyne; R Verdon; J-L Gérard; J-L Hanouz; J-L Fellahi
Journal:  Ann Fr Anesth Reanim       Date:  2011-12-06

6.  Inappropriate prescribing of aminoglycosides: risk factors and impact of an antibiotic control team.

Authors:  Jean-Ralph Zahar; Christophe Rioux; Emmanuelle Girou; Anne Hulin; Colette Sauve; Alexandra Bernier-Combes; Christian Brun-Buisson; Philippe Lesprit
Journal:  J Antimicrob Chemother       Date:  2006-07-24       Impact factor: 5.790

7.  Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis.

Authors:  Nasia Safdar; Jo Handelsman; Dennis G Maki
Journal:  Lancet Infect Dis       Date:  2004-08       Impact factor: 25.071

8.  Less is more: combination antibiotic therapy for the treatment of gram-negative bacteremia in pediatric patients.

Authors:  Pranita D Tamma; Alison E Turnbull; Anthony D Harris; Aaron M Milstone; Alice J Hsu; Sara E Cosgrove
Journal:  JAMA Pediatr       Date:  2013-10       Impact factor: 16.193

9.  Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America.

Authors:  Joseph S Solomkin; John E Mazuski; John S Bradley; Keith A Rodvold; Ellie J C Goldstein; Ellen J Baron; Patrick J O'Neill; Anthony W Chow; E Patchen Dellinger; Soumitra R Eachempati; Sherwood Gorbach; Mary Hilfiker; Addison K May; Avery B Nathens; Robert G Sawyer; John G Bartlett
Journal:  Clin Infect Dis       Date:  2010-01-15       Impact factor: 9.079

Review 10.  Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia.

Authors:  Mical Paul; Yaakov Dickstein; Agata Schlesinger; Simona Grozinsky-Glasberg; Karla Soares-Weiser; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2013-06-29
View more
  2 in total

1.  Application of guidelines for aminoglycosides use in French hospitals in 2013-2014.

Authors:  J Robert; Y Péan; S Alfandari; J-P Bru; J-P Bedos; C Rabaud; R Gauzit
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-01-09       Impact factor: 3.267

2.  Management of children with fever and neutropenia: results of a survey in 51 pediatric cancer centers in Germany, Austria, and Switzerland.

Authors:  Max Scheler; Thomas Lehrnbecher; Andreas H Groll; Ruth Volland; Hans-Jürgen Laws; Roland A Ammann; Philipp Agyeman; Andishe Attarbaschi; Margaux Lux; Arne Simon
Journal:  Infection       Date:  2020-06-10       Impact factor: 3.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.